A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]Xuanwu Hospital of Capital Medical University Beijing, Beijing, China, 100010[3]The Second Affiliated Hospital of Anhui Medical University Hefei, Anhui, China, 230001[4]Anhui Chest Hospital Hefei, Anhui, China, 230011[5]Yijishan Hospital of Wannan Medical College Wuhu, Anhui, China, 242400[6]Beijing Chest Hospital, Capital Medical University Beijing, Beijing, China, 100010[7]Peking University Third Hospital Beijing, Beijing, China, 100010
研究目的：
This is a randomized, double-blind, multicenter phase III clinical study to evaluate efficacy and safety of anlotinib hydrochloride capsule combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in subjects with advanced non-squamous cell non-small cell lung cancer.
